Ceftriaxone is a bactericidal cephalosporin antibiotic that inhibits bacterial cell wall synthesis and remains stable against many beta-lactamases.

Treatment of infections caused by susceptible bacteria including:

• Lower respiratory tract, skin and soft tissue, urinary tract, bone and joint infections

• Meningitis, septicemia, gonorrhea, pelvic inflammatory disease

• Intra-abdominal infections

• Surgical prophylaxis

• Adults: 1–2 g once daily or in two divided doses; up to 4 g/day for serious infections.

• Pediatrics: 50–75 mg/kg once or twice daily; for meningitis, initial dose 100 mg/kg/day (max 4 g).

• Neonates: Contraindicated in hyperbilirubinemic neonates; avoid concurrent calcium-containing IVs

Commonly reported reactions include Injection site pain/phlebitis, rash, eosinophilia, leukopenia, thrombocytosis, diarrhea, elevated liver enzymes, BUN, and creatinine, rare but serious: encephalopathy, seizures, hemolytic anemia, and C. difficile-associated diarrhea

Ceftriaxone Injection is contraindicated in patients with known allergy to the cephalosporin class of antibiotics. Solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products.

Hyperbilirubinemic neonates, especially prematures, should not be treated with Ceftriaxone Injection. In vitro studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to a possible risk of bilirubin encephalopathy in these patients.

• Avoid in neonates receiving calcium-containing IV solutions.

• Risk of serious allergic reactions, including anaphylaxis.

• Monitor for signs of Clostridioides difficile infection, hemolytic anemia, and neurological symptoms in renal impairment.

• Possible biliary sludge and gallbladder issues on ultrasound; discontinue if symptomatic